Nabumetone
RELAFEN · relifex · Nabumeton · brl147777 · BRL-14777 · NABUMETONE · Nabumetone RS · Naftobumedone
식별자 및 물리적 특성
| CAS No. | 42924-53-8 |
|---|---|
| 분자식 | C15H16O2 |
| 평균 분자량 | 228.29 g/mol |
| 단동위원소 질량 | 228.11502975 g/mol |
| SMILES | COc1ccc2cc(CCC(C)=O)ccc2c1 |
| InChIKey | BLXXJMDCKKHMKV-UHFFFAOYSA-N |
| PubChem CID | 4409 |
| ChEMBL | CHEMBL1070 |
| ChEBI | CHEBI:7443 |
| EC No. | 641-917-1 |
| DTXSID | DTXSID4045472 |
화학 및 물리적 성질
| XLogP | 3.1 |
|---|---|
| 극성 표면적 | 26.3 |
| 수소 결합 공여자 수 | 0 |
| 수소 결합 수용자 수 | 2 |
| 회전 가능 결합 수 | 4 |
| 무거운 원자 수 | 17 |
| 형식 전하 | 0 |
| 복잡도 | 262 |
| 의약품 | PharmaceuticalsPharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 3.13.45 |
| 용해도 | Practically insoluble1.93e-03 g/L알코올이나 클로로포름에 용해됨 |
| Human Drugs | Breast FeedingLactationMilk, HumanAnalgesic AgentsAnti-inflammatory Agents, NonsteroidalFDA approved drugs -> Active ingredientPharmaceuticals |
| 녹는점 | 78-8280 °C80-810C |
| Physical Description | Solid |
| Collision Cross Section | 148.38 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]148 Ų [M+H]+ [CCS Type: TW |
| 끓는 점 | 330.1°C (rough estimate) |
| 밀도 | 1.0657 (rough estimate) |
| 굴절률 | 1.5542 (estimate) |
| 저장 조건 | Sealed in dry,2-8°C |
| 물리적 상태 | Solid |
| 색상 | 하얀색 |
| 용해도 | 6mg/L(22.5℃) |
| BCS Class | 2/4 |
| 주요 응용 | 법의학 및 독성학의약품(소분자)수의사 |
| InChI | InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3 |
| InChIKey | BLXXJMDCKKHMKV-UHFFFAOYSA-N |
| SMILES | CC(=O)CCC1=CC=C2C(=C1)C=CC(OC)=C2 |
| NIST | Nabumetone(42924-53-8) |
화학적 성질
White Powder
안전 및 규제
| GHS 분류 | This chemical does not meet GHS hazard criteria for 14.3% (1 of 7) of reports.WarningH302 (42.9%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 7 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (42.9%) |
| Protective Action Criteria (PAC) | 1.0 [mg/m3]11 [mg/m3]66 [mg/m3] |
| Hepatotoxicity | Prospective studies show that 1% to 5% of patients taking nabumetone experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (above 3 times ULN) occur in 0.5% of patients, a rate similar to that in placebo treated controls. Clinically apparent liver injury with jaundice from nabumetone is rare and in large clinical trials, no instances of acute liver injury with jaundice were reported. Since its approval and release, nabumetone has been reported to cause rare instances of serious hepatic adverse events (~1.3 per million prescriptions), but there have been no cases of clinically apparent liver injury due to nabumetone described in the published literature. Furthermore, nabumetone is not mentioned as a cause in large case series on drug induced liver injury or acute liver failure. Thus, the latency, clinical features and outcome of nabumetone induced liver injury have not been described and clinically apparent hepatotoxicity due to nabumetone must be very rare. |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)NabumetoneAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 수질 위해 등급(WGK) | 2 |
| RTECS 번호 | EL9085000 |
| 관세 코드 | 2914500000 |
| 위험 문구(R) | 22-40 |
| 위험 표시 | Xn |
| 안전 문구(S) | 36/37 |
| 저장 분류 | 11 - Combustible Solids |
용도
개요
Nabumetone is a non-acidic, nonsteroidal antiinflammatory agent formally related to naproxen. Its main circulating metabolite is 6-methoxy-2-naphthylacetic acid (α-nornaproxen). Administered once daily (Tsub>1/2 * 30 hrs), nabumetone is reported to be effective in the treatment of rheumatoid and osteoarthritis.
용도
Nabumetone is an anti-inflammatory and antibacterial agent (1). A non-steroidal anti-inflammatory prodrug used for treatment of inflammatory and degenerative rheumatic diseases.
일반 설명
Nabumetone (Relafen), a nonacidic NSAID prodrug, isclassified as an arylacetic acid, because it undergoes rapidhepatic metabolism to its active metabolite, 6-methoxy-2-naphthylacetic acid. Similar to the other arylacetic aciddrugs, it is used in short- or long-term management of RAand OA. Being nonacidic, it does not produce significantprimary insult to the GI mucosa lining and also has no effecton prostaglandin synthesis in gastric mucosa, thus producingminimum secondary GI damage when comparedwith other conventional NSAIDs.